Chimerix (NASDAQ:CMRX)

CAPS Rating: 3 out of 5

Caps

How do you think CMRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

50 Outperform
5 Underperform
 

All-Star Players

15 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top CMRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.85)
Submitted May 19, 2016

It's hard to get enthusiastic about Chimerix but I've done pretty well on this stock both long and short, on CAPS and in real life. Right now my instincts are telling me the stock is oversold and brincidofovir is not dead. Market cap is 210M, cash is… More

zzlangerhans (99.85)
Submitted September 09, 2014

Chimerix is ripping of late and I smell a rat. The stock was ailing in May even after the company solved their compassionate use PR nightmare, and management found the exact bottom of the stock to price a huge dilutive financing of 112M. Since then… More

CMRX VS S&P 500 (SPY)

Fools bullish on CMRX are also bullish on:

Fools bearish on CMRX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CMRX.

Recs

0
Member Avatar oscillation (77.35) Submitted: 5/21/2016 9:12:46 AM : Outperform Start Price: $4.72 CMRX Score: -61.16

nev

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 5/19/2016 3:42:56 PM : Outperform Start Price: $4.55 CMRX Score: -59.65

It's hard to get enthusiastic about Chimerix but I've done pretty well on this stock both long and short, on CAPS and in real life. Right now my instincts are telling me the stock is oversold and brincidofovir is not dead. Market cap is 210M, cash is 315M, no debt, and burn was 26M last quarter. Cash won't decline to the current market cap for a year. 36 week final data from the AdVise trial will be released in about three months and probably won't be worse than the 24 week data, possibly better. The smallpox indication is still alive and a second animal study will be performed later this year. Trials of iv brincidofovir will begin in Q3.

I just bought 2000 shares at 4.57. Unlike my previous trade which I closed for relatively small gains, I'll probably double down on this if the share price stays low over the next couple of weeks but doesn't totally tank.

Recs

0
Member Avatar Sparticus501 (< 20) Submitted: 10/10/2014 9:31:29 PM : Outperform Start Price: $32.71 CMRX Score: -133.33

Leading in the fight with Ebola.

Leaderboard

Find the members with the highest scoring picks in CMRX.

Score Leader

zzlangerhans

zzlangerhans (99.85) Score: +157.86

Huge dilutive financings at a low in share price are not the pathway to longterm sustainability in biotech.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BadPowerScore 75.78 9/17/2013 Underperform 5Y $19.68 -82.72% +60.04% +142.76 0 Comment
3barns < 20 10/3/2014 Underperform 5Y $30.46 -88.84% +39.44% +128.28 1 Comment
Slickrick9565 54.62 1/7/2016 Underperform 5Y $8.78 -61.28% +40.14% +101.41 0 Comment
chushogi 68.67 11/7/2016 Underperform 5Y $3.75 -9.33% +29.45% +38.79 0 Comment
TheSlightEdge 99.06 9/13/2018 Underperform 5Y $3.76 -9.57% -5.71% +3.86 0 Comment
flypower 98.30 8/2/2016 Outperform 5Y $3.98 -14.47% +26.99% -41.46 0 Comment
superstar2 99.55 7/6/2016 Outperform 5Y $3.91 -13.04% +30.64% -43.68 0 Comment
gunda7907 < 20 6/14/2016 Outperform 5Y $3.90 -12.82% +31.97% -44.79 0 Comment
portefeuille4 99.58 9/2/2016 Outperform 5Y $4.62 -26.41% +25.51% -51.92 0 Comment
portefeuille2 99.12 9/2/2016 Outperform 5Y $4.74 -28.27% +25.27% -53.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CMRX.

Advertisement